AIM
RVNC

Assured Investment Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Assured Investment Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-11,388
Closed -$179K – 908
2019
Q1 		$179K Sell
11,388
-2,292
-17% -$39.7K ﹤0.01% 818
2018
Q4 		$275K Buy
13,680
+10,704
+360% +$236K 0.01% 822
2018
Q3 		$74K Buy
+2,976
New +$80.9K ﹤0.01% 1069
2018
Q2 		– Sell
-13,177
Closed -$406K – 1357
2018
Q1 		$406K Buy
+13,177
New +$424K 0.01% 835

Other funds holding RVNC

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Assured Investment Management's RVNC Position: Q2 2019 in Review

Assured Investment Management sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2019, closing a stake of 11,388 shares — an estimated $179K sold.

Assured Investment Management first reported a position in RVNC in Q1 2018 and held it in 4 quarters. The position peaked at $406K in Q1 2018. 114 funds tracked by Wall St. Rank hold RVNC as of Q2 2019.

  • Assured Investment Management reported no remaining Revance Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
  • Assured Investment Management sold 11,388 Revance Therapeutics, Inc. shares in Q2 2019, an estimated $179K.
  • Assured Investment Management first reported a position in Revance Therapeutics, Inc. in Q1 2018 and held it in 4 quarters.
  • Assured Investment Management's Revance Therapeutics, Inc. position peaked at $406K in Q1 2018.
  • 114 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2019.

Based on Assured Investment Management's 13F filing for Q2 2019, filed 14 Aug 2019.